Know Cancer

forgot password

An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies

Phase 3
18 Years
Not Enrolling
Brain Edema, Brain Tumor

Thank you

Trial Information

An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies

XERECEPT® is not a potential treatment for cancer, but may reduce the edema associated with
tumors and as a result, decrease neurological symptoms.

Inclusion Criteria:

- Participation in and completion of stipulated final follow-up periods for study NTI
0302, NTI 0303, or other designated studies.

- Have a Karnofsky Performance of > 50 at Baseline

- Capable of self-administration of subcutaneous injections twice daily or availability
of assistance from caregiver.

- Ability to provide written informed consent or, if unable to provide, have a legal
guardian or representative provide written informed consent.

- For women of childbearing potential: a negative serum pregnancy test at Baseline

Exclusion Criteria:

- Concurrent enrollment in any investigational drug or device study, other than NTI
0302, NTI 0303, or other designated studies.

- Systemic steroid use for any indication other than peritumoral brain edema.

- Use or intended use of dexamethasone as an anti-emetic during study.

- Clinical signs and symptoms of cerebral herniation.

- Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine
metabolic disease which could put the patient at unusual risk during study

- Confounding previous or concurrent neurological disorders that would interfere with
adequate clinical evaluation.

- Clinically significant head injury or chronic seizure disorder, if the condition
results in functional impairment or is likely to interfere with
evaluations.(Maintenance anticonvulsant therapy is allowed)

- Central nervous system (CNS) infection.

- Pregnancy, breastfeeding and/or refusal to practice birth control while in study, for
women of childbearing potential.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Long Term Safety and Tolerability of hCRF

Outcome Description:

Number of patients reporting adverse events

Outcome Time Frame:


Safety Issue:


Principal Investigator

William Shapiro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Barrow Neurological Institute


United States: Food and Drug Administration

Study ID:

NTI 0501



Start Date:

July 2005

Completion Date:

April 2009

Related Keywords:

  • Brain Edema
  • Brain Tumor
  • peritumoral brain edema
  • edema
  • malignant brain tumor
  • astrocytoma
  • brain tumor
  • dexamethasone
  • Decadron
  • Brain Edema
  • Brain Neoplasms
  • Edema



Memorial Sloan Kettering Cancer Center New York, New York  10021
Stanford University Medical Center Stanford, California  94305-5408
University of Colorado Cancer Center Denver, Colorado  80262
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Hoag Memorial Hospital Presbyterian Newport Beach, California  92658
Medical College of Wisconsin Milwaukee, Wisconsin  53226
Weill Medical College of Cornell University New York, New York  10021
Mayo Clinic Jacksonville, Florida  32224
Good Samaritan Hospital Dayton, Ohio  45406
Evanston Northwestern Healthcare Evanston, Illinois  60201
The Ohio State University Columbus, Ohio  43210
Barrow Neurological Institute Phoenix, Arizona  85013
Moffitt Cancer Center Tampa, Florida  33612
University of Wisconsin Madison,, Wisconsin  53792-5666
Dent Neurologic Institute Amherst, New York  14226
UC Davis Medical Center, Division of Medical Oncology Sacramento, California  95817
Cancer Institute of Orlando Orlando, Florida  32804
Winship Cancer Institute, Emory University Atlanta, Georgia  30322
Hermelin Brain Tumor Center, Henry Ford Hospital Detroit, Michigan  48202
University Hematology Oncology Care, LLC Cincinnati, Ohio  43210
Oregon Clinic Portland, Oregon  97210
Virginia Mason Clinic Seattle, Washington  98111
UC San Diego Cancer Center San Diego, California  92037
Colorado Neurological Institute Center for Brain & Spinal Tumors Englewood, Colorado  80113
Feinberg School of Medicine, Northwestern University Chicago, Illinois  60611